Boston Scientific (NYSE:BSX) Updates Q2 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.820-0.840 for the period, compared to the consensus earnings per share estimate of 0.860. The company issued revenue guidance of $5.3 billion-$5.4 billion, compared to the consensus revenue estimate of $5.6 billion. Boston Scientific also updated its FY 2026 guidance to 3.340-3.410 EPS.

Boston Scientific Price Performance

Shares of BSX stock traded up $4.99 on Wednesday, reaching $64.51. 7,597,011 shares of the company were exchanged, compared to its average volume of 15,634,536. The company has a market cap of $95.88 billion, a price-to-earnings ratio of 33.37, a P/E/G ratio of 0.94 and a beta of 0.78. The business has a 50-day moving average price of $69.04 and a 200 day moving average price of $86.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific has a 1 year low of $59.38 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific will post 3.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BSX shares. Mizuho lowered their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Jefferies Financial Group restated a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Boston Scientific in a research report on Monday, March 30th. National Bank Financial set a $115.00 price target on shares of Boston Scientific in a research report on Monday, February 2nd. Finally, Stifel Nicolaus decreased their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $101.50.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.34% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results showed durable topline growth and a small EPS beat: net sales of $5.203B (up ~11.6% year/year) and adjusted EPS $0.80, slightly above consensus; GAAP net income rose sharply year over year — a signal that demand for core devices remains solid. Boston Scientific announces results for first quarter 2026
• Neutral Sentiment: Several sell‑side firms have adjusted models/price targets but many still rate BSX a Buy — analysts view the guidance cut as a potential reset that creates longer‑term upside if execution rebounds. Boston Scientific Stock Is Trending Today: What To Know Now
• Neutral Sentiment: Unusually high options activity (large call purchases) and elevated trading volume ahead of the print indicate traders positioned for volatility rather than a clear directional conviction; this can amplify intraday moves.
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance: FY EPS guide of $3.340–3.410 vs. ~3.45 consensus and Q2 EPS guide of $0.820–0.840 vs. ~0.86 consensus; revenue outlook was lowered as well — the guidance miss/trim is the primary near‑term negative catalyst. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple securities class‑action filings and investor‑notice campaigns (several law firms seeking lead plaintiffs; May 4 deadline) add headline/legal risk and can pressure sentiment and float until resolved. BSX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Recent reports of meaningful insider and institutional selling, plus prior analyst downgrades/target trims, increase near‑term supply pressure and reduce confidence until management demonstrates rehabbed guidance/trajectory.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in BSX. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Main Street Financial Solutions LLC raised its stake in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC increased its stake in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its stake in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.